Global Knee Osteoarthritis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Knee Osteoarthritis Market Size

• The global knee osteoarthritis market size was valued at USD 8.41 billion in 2025 and is expected to reach USD 17.12 billion by 2033, at a CAGR of 9.30% during the forecast period
• The market growth is largely driven by the rising prevalence of osteoarthritis, particularly among the aging population, alongside increasing obesity rates and sedentary lifestyles that contribute to joint degeneration and higher disease burden
• Furthermore, advancements in treatment approaches, including disease-modifying osteoarthritis drugs, regenerative therapies, hyaluronic acid injections, and minimally invasive surgical procedures, are enhancing patient outcomes and expanding therapeutic adoption

Knee Osteoarthritis Market Analysis

• Knee osteoarthritis, a degenerative joint disorder characterized by cartilage degradation and joint inflammation, is increasingly becoming a major public health concern, driving demand for effective diagnostic and treatment approaches across early and advanced stages of the disease
• The escalating demand for knee osteoarthritis management is primarily fueled by the rising aging population, increasing obesity rates, growing incidence of joint injuries, and higher awareness regarding early diagnosis and long-term disease management options
• North America dominated the knee osteoarthritis market with a significant revenue share of 38.6% in 2025, supported by advanced healthcare infrastructure, high diagnosis rates, strong reimbursement systems, and widespread adoption of advanced treatment options, with the U.S. leading due to robust clinical research and availability of innovative orthopedic care
• Asia-Pacific is expected to be the fastest growing region in the knee osteoarthritis market during the forecast period due to rapid urbanization, improving healthcare access, increasing healthcare expenditure, and a large aging population coupled with rising awareness of musculoskeletal disorders
• Medication segment dominated the knee osteoarthritis market with a substantial market share of 46.3% in 2025, driven by the widespread use of oral pain relievers, anti-inflammatory drugs, and injectable therapies that help manage symptoms, reduce inflammation, and improve joint function among patients

Report Scope and Knee Osteoarthritis Market Segmentation

Knee Osteoarthritis Market Trends

“Advancements in Regenerative and Personalized Treatment Approaches”

• A significant and accelerating trend in the global knee osteoarthritis market is the growing adoption of regenerative therapies and personalized treatment approaches, including platelet-rich plasma (PRP), stem cell therapy, and patient-specific care plans aimed at improving outcomes and slowing disease progression
• For instance, PRP injections are increasingly being used in clinical practice to reduce inflammation and promote tissue repair in early to moderate knee osteoarthritis patients, offering a minimally invasive alternative to traditional treatments. Similarly, stem cell-based therapies are being explored to regenerate cartilage and enhance joint function
• Advancements in diagnostics and imaging technologies are enabling earlier and more accurate detection of knee osteoarthritis, allowing clinicians to tailor treatment strategies based on disease severity and patient condition, thereby improving long-term management. Furthermore, the integration of digital health tools and AI-based monitoring is helping track patient progress and optimize therapy outcomes
• The shift toward non-surgical and minimally invasive interventions is transforming patient expectations, with increasing preference for therapies that reduce recovery time, hospital visits, and surgical risks while maintaining effective symptom control
• Moreover, increasing clinical research and pipeline developments focused on disease-modifying osteoarthritis drugs (DMOADs) are expected to redefine treatment paradigms by targeting the underlying disease progression rather than only symptom relief
• This trend towards innovative, patient-centric, and technology-enabled treatment solutions is reshaping clinical practices, with companies and healthcare providers focusing on expanding access to advanced therapies and improving overall quality of care in knee osteoarthritis management

Knee Osteoarthritis Market Dynamics

Driver

“Rising Prevalence of Osteoarthritis and Aging Population”

• The increasing prevalence of knee osteoarthritis due to a rapidly aging global population, combined with rising obesity rates and sedentary lifestyles, is a significant driver for the growing demand for effective treatment and diagnostic solutions
• For instance, the growing elderly population worldwide is more susceptible to joint degeneration, leading to a higher incidence of knee osteoarthritis cases requiring medical intervention and long-term disease management
• As patients experience chronic pain, stiffness, and reduced mobility, there is an increasing reliance on medications, therapies, and surgical procedures to improve quality of life and restore joint function
• Furthermore, improved awareness of early diagnosis and the availability of advanced treatment options are encouraging more individuals to seek timely medical care, contributing to higher diagnosis rates and treatment adoption
• In addition, increasing healthcare expenditure and expanding access to orthopedic care services in emerging economies are supporting wider adoption of knee osteoarthritis treatments
• Moreover, growing participation in sports and physical activities, leading to higher incidence of joint injuries, is further contributing to the rising patient pool requiring osteoarthritis management
• The growing healthcare infrastructure, coupled with increased spending on musculoskeletal disorders and advancements in orthopedic care, is further supporting market expansion across both developed and emerging economies

Restraint/Challenge

“High Treatment Costs and Limited Access to Advanced Therapies”

• Concerns surrounding the high cost of advanced treatments and limited accessibility in certain regions pose a significant challenge to broader market penetration of knee osteoarthritis therapies
• For instance, regenerative therapies such as stem cell treatments and some biologic interventions are often expensive and not widely covered by insurance, making them less accessible to a large portion of the patient population
• Addressing affordability issues through improved reimbursement policies, cost-effective treatment options, and wider availability of generic medications is crucial for increasing patient adoption and market reach. In addition, disparities in healthcare infrastructure between developed and developing regions can limit access to early diagnosis and advanced care
• While awareness of knee osteoarthritis is increasing, delays in diagnosis and treatment initiation remain common in low-resource settings, further hindering optimal disease management
• Furthermore, the need for long-term and repeated treatment cycles increases the overall financial burden on patients, limiting adherence to prescribed therapies
• In addition, variability in clinical outcomes for advanced therapies such as biologics and regenerative treatments may create hesitation among both patients and healthcare providers
• Overcoming these challenges through expanded healthcare access, policy support, and the development of affordable and scalable treatment solutions will be vital for sustained growth of the knee osteoarthritis market

Knee Osteoarthritis Market Scope

The market is segmented on the basis of treatment type, route of administration, dosage form, diagnosis, end-users, and distribution channel.

• By Treatment Type

On the basis of treatment type, the knee osteoarthritis market is segmented into medication, surgery, and therapy. The medication segment dominated the market with the largest market revenue share of 46.3% in 2025, driven by the widespread use of oral analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and injectable treatments that provide effective symptom relief and inflammation control. Patients and healthcare providers often prefer medications as the first line of treatment due to their accessibility, affordability, and non-invasive nature. The growing availability of both prescription and over-the-counter drugs further supports this segment’s dominance across all stages of the disease. In addition, increasing use of intra-articular injections such as hyaluronic acid and corticosteroids contributes to sustained demand. The segment benefits from continuous product innovations aimed at improving efficacy and reducing side effects.

The therapy segment is expected to witness the fastest growth rate of 12.8% from 2026 to 2033, fueled by increasing adoption of physical therapy, occupational therapy, and emerging regenerative approaches such as platelet-rich plasma (PRP) and stem cell therapy. These therapies are gaining traction as they focus on improving joint function, reducing pain, and delaying the need for surgical intervention. Rising patient preference for non-invasive and long-term management solutions is further accelerating adoption. Growing awareness about rehabilitation programs and lifestyle modifications is also supporting this segment. Moreover, integration of therapy with pharmacological treatments is increasingly being recognized as a comprehensive approach to disease management.

• By Route of Administration

On the basis of route of administration, the knee osteoarthritis market is segmented into oral, parenteral, and others. The oral segment dominated the market with the largest market revenue share of 52.1% in 2025, driven by the widespread use of oral medications such as NSAIDs, acetaminophen, and disease-modifying supplements that are easy to administer and widely available. Oral drugs are typically the first line of treatment due to their convenience, affordability, and patient compliance. They are extensively prescribed for managing mild to moderate symptoms and are available in both branded and generic forms. The ease of distribution through retail and hospital pharmacies further strengthens this segment’s position. In addition, continuous drug development efforts are enhancing the effectiveness and safety profiles of oral therapies.

The parenteral segment is expected to witness the fastest growth rate of 13.5% from 2026 to 2033, driven by increasing use of injectable therapies such as corticosteroids, hyaluronic acid, and biologics administered directly into the joint. These treatments provide faster and more targeted relief, making them suitable for moderate to severe cases. Growing preference for minimally invasive procedures is supporting the adoption of parenteral therapies. Furthermore, advancements in injection techniques and rising availability of outpatient procedures are contributing to segment growth. Increasing clinical acceptance of biologics and regenerative injectables is also accelerating demand in this category.

• By Dosage Form

On the basis of dosage form, the knee osteoarthritis market is segmented into tablets, injections, and others. The tablets segment dominated the market with the largest market revenue share of 48.7% in 2025, driven by the extensive use of oral solid dosage forms for pain management and inflammation control. Tablets are widely preferred due to their ease of consumption, accurate dosing, and cost-effectiveness. They are readily available through multiple distribution channels and are commonly prescribed in both acute and chronic treatment regimens. The availability of extended-release formulations and combination drugs further enhances their therapeutic value. In addition, strong patient adherence to tablet-based therapies supports sustained demand.

The injections segment is expected to witness the fastest growth rate of 14.2% from 2026 to 2033, fueled by increasing adoption of intra-articular therapies such as corticosteroid injections, hyaluronic acid, and regenerative biologics. Injections provide localized treatment with faster onset of action, making them highly effective for patients with moderate to severe symptoms. Rising preference for minimally invasive procedures and growing clinical evidence supporting injectable therapies are driving this segment. Moreover, advancements in drug delivery technologies and increasing availability of outpatient injection procedures are contributing to growth. The segment is also benefiting from increasing use of PRP and stem cell-based injectables.

• By Diagnosis

On the basis of diagnosis, the knee osteoarthritis market is segmented into imaging tests, joint fluid analysis, blood tests, and others. The imaging tests segment dominated the market with the largest market revenue share of 57.4% in 2025, driven by the widespread use of X-rays, MRI, and CT scans for accurate assessment of joint damage, cartilage loss, and disease progression. Imaging techniques are considered the gold standard for diagnosing knee osteoarthritis and monitoring its severity. They provide detailed visualization of bone and soft tissue structures, enabling precise clinical evaluation. Increasing availability of advanced imaging technologies and improved diagnostic infrastructure further support this segment’s dominance. In addition, early detection through imaging is becoming more common due to rising awareness among patients and physicians.

The imaging tests segment is also expected to witness the fastest growth rate of 10.9% from 2026 to 2033, driven by technological advancements in diagnostic imaging and increasing adoption of AI-assisted interpretation tools. Enhanced imaging resolution and faster scanning techniques are improving diagnostic accuracy and efficiency. Growing emphasis on early and accurate diagnosis is encouraging wider use of imaging modalities. Furthermore, increasing healthcare investments and expansion of diagnostic centers in emerging markets are supporting segment growth. The integration of digital imaging with electronic health records is also streamlining diagnosis and patient management processes.

• By End-Users

On the basis of end-users, the knee osteoarthritis market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment dominated the market with the largest market revenue share of 49.8% in 2025, driven by the availability of advanced diagnostic facilities, skilled healthcare professionals, and comprehensive treatment options under one roof. Hospitals serve as primary centers for both diagnosis and treatment of moderate to severe knee osteoarthritis cases, including surgical interventions. The presence of multidisciplinary teams and access to advanced imaging and surgical equipment further strengthen this segment. Hospitals also handle a large volume of patient inflow, contributing to their dominant market position. In addition, strong reimbursement frameworks for hospital-based treatments support segment growth.

The homecare segment is expected to witness the fastest growth rate of 13.1% from 2026 to 2033, fueled by the increasing preference for remote patient management, rehabilitation programs, and long-term care at home. Growing adoption of telemedicine and digital health platforms is enabling continuous monitoring and consultation without hospital visits. Home-based physiotherapy and self-managed treatment plans are gaining popularity among elderly patients. Rising healthcare costs and the convenience of receiving care at home are further driving this segment. In addition, advancements in portable medical devices and remote monitoring tools are supporting the expansion of homecare services.

• By Distribution Channel

On the basis of distribution channel, the knee osteoarthritis market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment dominated the market with the largest market revenue share of 44.6% in 2025, driven by the high volume of prescriptions generated within hospital settings and the immediate availability of medications for inpatient and outpatient care. Hospital pharmacies play a critical role in dispensing drugs for post-diagnosis and post-surgical treatments. The integration of hospital pharmacies with treatment facilities ensures timely access to medications. In addition, the presence of specialized pharmacists and controlled drug management systems supports this segment’s dominance. Strong reliance on hospital-based care for moderate to severe cases further contributes to its leading position.

The online pharmacy segment is expected to witness the fastest growth rate of 15.3% from 2026 to 2033, driven by increasing digitalization, convenience of home delivery, and rising adoption of e-commerce platforms for healthcare products. Patients prefer online pharmacies for easy access to medications, competitive pricing, and subscription-based delivery models. The expansion of telemedicine services and digital prescriptions is further boosting online drug sales. Growing internet penetration and smartphone usage are also supporting segment growth, particularly in urban areas. In addition, discounts, wide product availability, and improved logistics are enhancing the attractiveness of online pharmacy channels.

Knee Osteoarthritis Market Regional Analysis

• North America dominated the knee osteoarthritis market with a significant revenue share of 38.6% in 2025, supported by advanced healthcare infrastructure, high diagnosis rates, strong reimbursement systems, and widespread adoption of advanced treatment options
• Patients and healthcare providers in the region benefit from early diagnosis, widespread availability of advanced therapies such as biologics, injectables, and minimally invasive surgical procedures, along with well-established reimbursement systems
• This widespread adoption is further supported by a rapidly aging population, high obesity rates, increasing healthcare expenditure, and a strong focus on research and clinical advancements, establishing knee osteoarthritis treatments as a key component of musculoskeletal care across both residential and clinical healthcare settings

U.S. Knee Osteoarthritis Market Insight

The U.S. knee osteoarthritis market captured the largest revenue share of 81% in North America in 2025, driven by a high prevalence of osteoarthritis, advanced healthcare infrastructure, and widespread adoption of innovative treatment options. Patients and healthcare providers are increasingly prioritizing early diagnosis and effective disease management through medications, injectable therapies, and minimally invasive procedures. The growing preference for advanced biologics, regenerative therapies, and outpatient orthopedic care further propels market growth. Moreover, the integration of digital health tools, strong reimbursement frameworks, and active clinical research are significantly contributing to the expansion of knee osteoarthritis treatment adoption across the country.

Europe Knee Osteoarthritis Market Insight

The Europe knee osteoarthritis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by an aging population, increasing prevalence of musculoskeletal disorders, and well-established healthcare systems. The rise in awareness regarding early diagnosis and the availability of advanced treatment options such as injectables, physiotherapy, and surgical interventions is fostering market adoption. European countries are also witnessing growing investments in orthopedic care and rehabilitation services. Furthermore, supportive healthcare policies, increasing healthcare expenditure, and expanding access to diagnostic imaging and specialist clinics are contributing to the steady growth of the market across residential and clinical settings.

U.K. Knee Osteoarthritis Market Insight

The U.K. knee osteoarthritis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing cases of osteoarthritis linked to an aging population and rising obesity rates. In addition, growing awareness regarding joint health and early intervention is encouraging patients to seek timely diagnosis and treatment. The National Health Service (NHS) plays a significant role in providing access to diagnostic and treatment services, including physiotherapy and surgical procedures. The adoption of minimally invasive treatments and rehabilitation programs is also gaining traction, supported by advancements in orthopedic care and a strong network of healthcare providers across the country.

Germany Knee Osteoarthritis Market Insight

The Germany knee osteoarthritis market is expected to expand at a considerable CAGR during the forecast period, fueled by a well-developed healthcare system, high diagnostic rates, and increasing demand for advanced orthopedic treatments. Germany’s emphasis on innovation and high-quality medical care supports the adoption of therapies such as injections, physiotherapy, and surgical interventions. The country’s aging population and growing awareness of degenerative joint diseases are key factors driving demand. In addition, strong focus on rehabilitation, preventive care, and integration of advanced imaging technologies is enhancing early diagnosis and effective management of knee osteoarthritis across both hospital and specialty clinic settings.

Asia-Pacific Knee Osteoarthritis Market Insight

The Asia-Pacific knee osteoarthritis market is poised to grow at the fastest CAGR of 12.4% during the forecast period of 2026 to 2033, driven by a rapidly aging population, increasing obesity rates, and improving healthcare infrastructure in countries such as China, Japan, and India. The region’s growing awareness of musculoskeletal disorders and expanding access to diagnostic and treatment facilities are supporting market growth. In addition, rising healthcare expenditure, government initiatives to strengthen healthcare systems, and increasing availability of affordable treatment options are driving adoption. The region is also witnessing growth in outpatient care, physiotherapy services, and minimally invasive procedures, contributing to broader market expansion.

Japan Knee Osteoarthritis Market Insight

The Japan knee osteoarthritis market is gaining momentum due to the country’s rapidly aging population and high prevalence of joint-related disorders. The demand for advanced and minimally invasive treatments is increasing, supported by Japan’s technologically advanced healthcare infrastructure. Patients and providers are increasingly adopting therapies such as intra-articular injections, physiotherapy, and surgical interventions to manage symptoms and improve mobility. In addition, strong emphasis on early diagnosis through imaging techniques and continuous monitoring is supporting effective disease management. The integration of rehabilitation services and patient-centric care approaches is further fueling growth in both hospital and outpatient settings.

India Knee Osteoarthritis Market Insight

The India knee osteoarthritis market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country’s large population base, rising geriatric population, and increasing prevalence of lifestyle-related risk factors such as obesity and physical inactivity. India is witnessing growing awareness regarding joint health and improved access to diagnostic services, including imaging and clinical evaluations. The availability of affordable treatment options, expansion of healthcare infrastructure, and growth of specialty orthopedic clinics are key factors propelling market growth. In addition, increasing adoption of physiotherapy, injectable therapies, and surgical procedures, along with government initiatives to improve healthcare access, is driving the expansion of the knee osteoarthritis market in the country.

Knee Osteoarthritis Market Share

The Knee Osteoarthritis industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• GSK plc (U.K.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Anika Therapeutics Inc. (U.S.)
• Bioventus LLC (U.S.)
• Ferring Pharmaceuticals (Switzerland)
• Seikagaku Corporation (Japan)
• Zimmer Biomet (U.S.)
• Stryker (U.S.)
• Smith & Nephew (U.K.)
• DePuy Synthes (U.S.)
• Haleon plc (U.K.)
• Ono Pharmaceutical Co., Ltd. (Japan)

What are the Recent Developments in Global Knee Osteoarthritis Market?

• In January 2026, results from a Phase 3 clinical study showed that Stempeutics’ cell therapy Stempeucel-OA demonstrated sustained clinical benefits and cartilage preservation over 24 months in knee osteoarthritis patients, suggesting potential disease-modifying effects beyond symptom relief
• In December 2025, Eli Lilly announced that its next-generation weight-loss drug retatrutide delivered substantial weight loss and significant knee osteoarthritis pain reduction in a global Phase 3 TRIUMPH-4 trial, with participants losing up to an average of ~28.7% body weight and notable improvements in pain and physical function
• In December 2025, Cipla, in partnership with Stempeutics Research, launched Ciplostem, an allogeneic mesenchymal stem cell therapy for knee osteoarthritis designed to reduce inflammation, enhance joint function, and preserve cartilage in Grade II and III patients, marking a significant orthobiologic therapy introduction
• In September 2025, a large meta-analysis published in PLOS One highlighted that non-drug therapies such as knee braces, hydrotherapy, and exercise significantly outperform traditional drug treatments in relieving knee osteoarthritis pain and improving mobility, potentially influencing clinical management guidelines
• In July 2024, early clinical data from an investigational stem cell therapy (MAG200) showed that a single injection improved pain and function for up to 12 months in ~75% of knee osteoarthritis participants, indicating ongoing innovation in regenerative approaches

SKU-54000